Xiangxue Pharmaceutical Co.,Ltd. (300147.SZ)
CNY 6.16
(5.12%)
CNY 6.16
(5.12%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 151.21 Million CNY | 194.35% |
| 2022 | 89.36 Million CNY | -51.67% |
| 2021 | -238.11 Million CNY | -60.09% |
| 2020 | 319.62 Million CNY | 18.8% |
| 2019 | 412.42 Million CNY | -11.06% |
| 2018 | 370.33 Million CNY | 3.29% |
| 2017 | 405.33 Million CNY | 42.16% |
| 2016 | 289.99 Million CNY | -20.3% |
| 2015 | 357.68 Million CNY | 0.69% |
| 2014 | 365.01 Million CNY | 19.31% |
| 2013 | 308.04 Million CNY | 53.43% |
| 2012 | 202.25 Million CNY | 40.32% |
| 2011 | 143.86 Million CNY | 17.0% |
| 2010 | 122.21 Million CNY | 41.01% |
| 2009 | 86.18 Million CNY | -61.41% |
| 2008 | 62.22 Million CNY | 323.73% |
| 2007 | 51.98 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 9.9 Million CNY | -88.4% |
| 2024 Q1 | 26.98 Million CNY | 142.01% |
| 2024 Q3 | -4.18 Million CNY | -142.28% |
| 2023 Q4 | -78.42 Million CNY | -1199.02% |
| 2023 Q2 | 44.69 Million CNY | -31.77% |
| 2023 Q3 | -6.03 Million CNY | -113.51% |
| 2023 FY | - CNY | 194.35% |
| 2023 Q1 | 65.5 Million CNY | 250.62% |
| 2022 Q4 | -43.49 Million CNY | -15.44% |
| 2022 FY | - CNY | -51.67% |
| 2022 Q1 | 24.18 Million CNY | 121.19% |
| 2022 Q3 | -37.67 Million CNY | 60.74% |
| 2022 Q2 | -95.95 Million CNY | -496.75% |
| 2021 FY | - CNY | -60.09% |
| 2021 Q4 | -114.13 Million CNY | -2067.49% |
| 2021 Q1 | 66.31 Million CNY | 5.73% |
| 2021 Q2 | 77 Million CNY | 16.11% |
| 2021 Q3 | 5.8 Million CNY | -92.47% |
| 2020 Q2 | 99.65 Million CNY | -28.56% |
| 2020 Q1 | 139.49 Million CNY | 331.7% |
| 2020 Q4 | 62.72 Million CNY | 110.66% |
| 2020 FY | - CNY | 18.8% |
| 2020 Q3 | 29.77 Million CNY | -70.12% |
| 2019 Q2 | 56.52 Million CNY | -38.63% |
| 2019 Q1 | 92.11 Million CNY | 70.91% |
| 2019 FY | - CNY | -11.06% |
| 2019 Q4 | 32.31 Million CNY | -65.72% |
| 2019 Q3 | 94.25 Million CNY | 66.74% |
| 2018 Q1 | 52.62 Million CNY | -70.47% |
| 2018 FY | - CNY | 3.29% |
| 2018 Q2 | 113.38 Million CNY | 115.48% |
| 2018 Q3 | 104.37 Million CNY | -7.95% |
| 2018 Q4 | 53.89 Million CNY | -48.36% |
| 2017 Q4 | 178.21 Million CNY | 505.38% |
| 2017 Q1 | 36.84 Million CNY | -60.63% |
| 2017 FY | - CNY | 42.16% |
| 2017 Q2 | 105.8 Million CNY | 187.17% |
| 2017 Q3 | 29.43 Million CNY | -72.18% |
| 2016 Q3 | 44.26 Million CNY | -3.26% |
| 2016 Q2 | 45.75 Million CNY | 27.39% |
| 2016 Q1 | 35.91 Million CNY | -59.6% |
| 2016 FY | - CNY | -20.3% |
| 2016 Q4 | 93.57 Million CNY | 111.42% |
| 2015 Q4 | 88.89 Million CNY | 28.35% |
| 2015 Q3 | 69.25 Million CNY | -18.67% |
| 2015 Q1 | 61.14 Million CNY | -43.75% |
| 2015 Q2 | 85.15 Million CNY | 39.28% |
| 2015 FY | - CNY | 0.69% |
| 2014 Q3 | 65.48 Million CNY | -24.09% |
| 2014 FY | - CNY | 19.31% |
| 2014 Q4 | 108.69 Million CNY | 65.98% |
| 2014 Q2 | 86.27 Million CNY | 51.7% |
| 2014 Q1 | 56.87 Million CNY | -45.87% |
| 2013 Q3 | 77.87 Million CNY | 18.63% |
| 2013 Q4 | 105.06 Million CNY | 34.91% |
| 2013 FY | - CNY | 53.43% |
| 2013 Q1 | 38.83 Million CNY | -33.69% |
| 2013 Q2 | 65.64 Million CNY | 69.02% |
| 2012 FY | - CNY | 40.32% |
| 2012 Q1 | 20.88 Million CNY | -57.67% |
| 2012 Q3 | 51.43 Million CNY | 33.29% |
| 2012 Q2 | 38.59 Million CNY | 84.76% |
| 2012 Q4 | 58.57 Million CNY | 13.88% |
| 2011 Q4 | 49.34 Million CNY | 34.19% |
| 2011 Q1 | 15.02 Million CNY | -57.67% |
| 2011 FY | - CNY | 17.0% |
| 2011 Q2 | 28.68 Million CNY | 90.96% |
| 2011 Q3 | 36.77 Million CNY | 28.19% |
| 2010 FY | - CNY | 41.01% |
| 2010 Q3 | 30.98 Million CNY | 31.35% |
| 2010 Q2 | 23.59 Million CNY | 64.45% |
| 2010 Q4 | 35.48 Million CNY | 14.51% |
| 2010 Q1 | 14.34 Million CNY | -34.42% |
| 2009 FY | - CNY | -61.41% |
| 2009 Q3 | 18.78 Million CNY | 0.0% |
| 2009 Q4 | 21.87 Million CNY | 16.46% |
| 2008 FY | - CNY | 323.73% |
| 2007 FY | - CNY | 0.0% |